Enjoy complimentary customisation on priority with our Enterprise License!
The Sepsis Therapeutics Market is estimated to grow by USD 1.42 billion, at a CAGR of 6.98% between 2023 and 2028. The global sepsis incidence is alarming, affecting millions annually. Antibiotic resistance and invasive procedures worsen the crisis. Precision medicine emerges as a crucial market driver, tailoring therapies to individual patients. Genetic, molecular, and immunological profiles shape treatments. In sepsis therapeutics, precision medicine fosters therapeutic innovation and aids clinical trials.
Rising disease awareness fuels the demand for effective medical interventions. However, upfront expenses hinder market growth, posing a challenge. Precision medicine trends prioritize tailored sepsis care, optimizing patient care and disease management. Regulatory compliance and quality assurance remain essential for pharmaceutical companies.
To learn more about this report, Request Free Sample
The hospitals segment is estimated to witness significant growth during the forecast period. The hospitals segment stands as the frontline institutions in the global market, representing critical hubs for the diagnosis, treatment, and management of sepsis cases. In addition, exemplary institutions like the Mayo Clinic, renowned for its patient-centered approach and innovative medical practices, showcase the comprehensive care provided to sepsis patients. Furthermore, the Cleveland Clinic, with its commitment to research-driven solutions and early intervention strategies, contributes significantly to improved sepsis outcomes.
Get a glance at the market contribution of various segments Download PDF Sample
The hospitals segment was the largest segment and was valued at USD 1.39 billion in 2018. Moreover, in hospitals, sepsis-therapeutics are administered across various departments, including emergency rooms, intensive care units (ICUs), and surgical wards, reflecting the urgency and complexity of sepsis-cases. In addition, these institutions prioritize protocols for prompt identification, aggressive treatment, and continuous monitoring, underscoring the crucial role hospitals play in combating sepsis. Furthermore, factors such as the ongoing advancements in hospital infrastructure, technological integration for swift diagnosis and treatment, and concerted efforts to enhance sepsis-awareness and management practices within these healthcare institutions globally are fueling the growth of this segment, which in turn drives the market growth during the forecast period.
The antimicrobial therapy segment is an essential aspect of Septicemia Therapy, comprising the use of medications to combat the underlying infectious agents. In addition, antibiotics play a central role in addressing bacterial infections associated with sepsis. Moreover, these drugs are administered through various routes, including intravenous, to ensure rapid and effective distribution throughout the body. In addition, timely initiation of antimicrobial therapy is pivotal, as it directly impacts the success of Septic Shock Intervention by halting the progression of the infection. Furthermore, advancements in precision medicine and a better understanding of microbial genomics are expected to fuel the evolution of antimicrobial therapy, ensuring its efficacy and relevance in the dynamic landscape of sepsis-treatment, which in turn drives the market growth during the forecast period.
For more insights about the market share of various regions Download PDF Sample now!
North America is projected to contribute 35% to the growth of the global market during the forecast period. Technavio’s analysts have extensively outlined the regional trends and drivers that will influence the market during this time. North America holds a pivotal role in the global sepsis treatment market, with the US and Canada emerging as major revenue contributors. The region boasts a highly advanced healthcare infrastructure, state-of-the-art medical research, and a robust regulatory framework. Institutions like the Mayo Clinic and Johns Hopkins Hospital in the US significantly contribute to advancements in sepsis diagnosis and treatment. Moreover, the region's high awareness among healthcare professionals and the public fuels the demand for effective therapeutics, thereby driving market growth in North America during the forecast.
The global incidence of sepsis is alarming, surpassing deaths from other diseases. Antibiotic resistance exacerbates the crisis, limiting treatment options. Precision medicine emerges as a market driver, tailoring therapies to patients' unique profiles. Genetic, molecular, and immunological factors shape treatment strategies. However, the growing threat of antimicrobial resistance poses a challenge.
Overuse and misuse of antibiotics contribute to resistant strains, narrowing treatment options. Effective hospital care and healthcare providers are crucial for patient management. Pharmaceutical companies play a key role in developing targeted therapies. Treatment guidelines and patient support groups aid in navigating treatment options.
The global incidence of sepsis is alarming, driven by factors such as antibiotic-resistant infections and increased invasive medical procedures. Precision medicine emerges as a pivotal market growth driver, tailoring treatments based on patients' genetic, molecular, and immunological profiles.
According to the CDC, sepsis claims the lives of 350,000 adults annually in the US alone, affecting 1.7 million individuals, surpassing deaths from opioid overdoses, breast cancer, and prostate cancer combined. Additionally, over 75,000 children in the US suffer from severe sepsis each year. Factors such as antibiotic-resistant infections, increased invasive medical procedures, and an aging population with compromised immune systems contribute to this surge. The emphasis on precision medicine shapes market research and growth analysis, guiding market forecasting. Pharmaceutical companies play a crucial role in developing tailored therapies, emphasizing brand recognition and effective distribution channels.
A significant market growth trend is the rising emphasis on precision medicine in treating infectious diseases like sepsis. This approach tailors therapies based on individual patient characteristics, including genetic, molecular, and immunological factors. It aims to move beyond the conventional approach, optimizing interventions for better outcomes.
For instance, identifying genetic variations can guide targeted therapies, and precision medicine helps determine the most effective antimicrobial agents. As a result, such factors contribute to market growth analysis in the forecast period, shaping strategies in the pharmaceutical industry and driving advancements in adjunctive therapies like immunotherapy and vasopressors for early sepsis detection.
The escalating challenge of antimicrobial resistance (AMR) poses a significant obstacle to market growth. AMR arises when microorganisms like bacteria, viruses, fungi, and parasites evolve to resist drugs intended to eradicate them. This resistance undermines the efficacy of antibiotics, crucial in treating bacterial infections. Excessive use and misuse of antibiotics in healthcare and agriculture expedite the emergence of resistant strains, amplifying the threat to public health.
Additionally, the limited availability of effective antibiotics restricts treatment options for sepsis patients, further impeding market growth drivers in the forecast period for pharmaceutical companies and providers of intravenous fluids.
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 16 market companies, including:
Adrenomed AG: The company offers sepsis therapeutics solutions such as Adrecizumab.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The market encompasses a range of treatments aimed at combating this life-threatening condition. From septic shock treatment to antibiotics, the focus is on swift sepsis diagnosis and effective infection control within the Intensive Care Unit (ICU). Therapeutic approaches include the use of anti-inflammatory drugs to modulate the immune response and targeted blood infection treatment to manage septicemia. Adherence to sepsis guidelines and advancements in critical care medicine are crucial in improving sepsis management and reducing sepsis mortality rates. Ongoing sepsis research seeks to deepen understanding of sepsis pathophysiology, enhance sepsis symptoms recognition, and refine sepsis prevention strategies for better sepsis prognosis.
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Market Customer Landscape
The market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2018 to 2028.
Market Scope |
|
Report Coverage |
Details |
Page number |
157 |
Base year |
2023 |
Historic period |
2018-2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 6.98% |
Market Growth 2024-2028 |
USD 1.42 billion |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
6.78 |
Regional analysis |
North America, Europe, APAC, South America, and Middle East and Africa |
Performing market contribution |
North America at 35% |
Key countries |
US, China, Japan, Germany, and UK |
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
Key companies profiled |
Adrenomed AG, AM Pharma BV, Astellas Pharma Inc., AstraZeneca Plc, bioMerieux SA, CytoSorbents Corp., F. Hoffmann La Roche Ltd., Hikma Pharmaceuticals Plc, Inotrem S.A., Novartis AG, Pfizer Inc., Sanofi SA, Spectral Medical Inc., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc. |
Market dynamics |
Parent market analysis, market growth and forecasting inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Download Sample PDF at your Fingertips
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Application
7 Market Segmentation by Type
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.